# OnCo record paper-andtbacka-optim-talimogene-jco-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-andtbacka-optim-talimogene-jco-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-andtbacka-optim-talimogene-jco-2015" ;
  schema:name "OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus"@en ;
  schema:description "Injecting an engineered herpes virus into melanoma lesions produced lasting shrinkage in about one patient in six, compared with one in fifty on the control drug, but it did not clearly help people live longer."@en ;
  schema:url <https://onco.cc/key-papers/paper-andtbacka-optim-talimogene-jco-2015/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2014.58.3377>, <https://pubmed.ncbi.nlm.nih.gov/26014293/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2014.58.3377> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Andtbacka RH, Kaufman HL, Collichio F, et al." ;
  onco:related <https://onco.cc/key-papers/paper-chesney-j-clin-oncol/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/talimogene-laherparepvec/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:people <https://onco.cc/people/howard-kaufman/> ;
  onco:journals <https://onco.cc/journals/jco/> .